Targeted Therapy
253 molecules in this therapeutic area. Open any product for its details, or send an inquiry directly.
Targeted Therapy (74)
| Molecule | Drug Class / Mechanism | Oncology Type | Inquiry | |
|---|---|---|---|---|
Jaktinib |
JAK Inhibitor | Hematologic (MPN) | ||
|
Molecule
Jaktinib
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (MPN)
Drug Class / Mechanism
JAK Inhibitor |
||||
Lanraplenib |
SYK / Multi-Kinase Inhibitor | Hematologic | ||
|
Molecule
Lanraplenib
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic
Drug Class / Mechanism
SYK / Multi-Kinase Inhibitor |
||||
Lisaftoclax |
BCL-2 Inhibitor | Hematologic | ||
|
Molecule
Lisaftoclax
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic
Drug Class / Mechanism
BCL-2 Inhibitor |
||||
LY3410738 (IDH1/2 Inhibitor) |
IDH1/2 Inhibitor | Hematologic (AML) | ||
|
Molecule
LY3410738 (IDH1/2 Inhibitor)
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (AML)
Drug Class / Mechanism
IDH1/2 Inhibitor |
||||
Marizomib |
Proteasome Inhibitor | Hematologic (Multiple Myeloma) | ||
|
Molecule
Marizomib
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Multiple Myeloma)
Drug Class / Mechanism
Proteasome Inhibitor |
||||
Midostaurin |
FLT3 Inhibitor | Hematologic (AML) | ||
|
Molecule
Midostaurin
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (AML)
Drug Class / Mechanism
FLT3 Inhibitor |
||||
Mocetinostat |
HDAC Inhibitor | Hematologic (Lymphoma) | ||
|
Molecule
Mocetinostat
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Lymphoma)
Drug Class / Mechanism
HDAC Inhibitor |
||||
Momelotinib |
JAK Inhibitor | Hematologic (MPN) | ||
|
Molecule
Momelotinib
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (MPN)
Drug Class / Mechanism
JAK Inhibitor |
||||
Navitoclax |
BCL-2 Inhibitor | Hematologic | ||
|
Molecule
Navitoclax
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic
Drug Class / Mechanism
BCL-2 Inhibitor |
||||
Obatoclax |
BCL-2 Inhibitor | Hematologic | ||
|
Molecule
Obatoclax
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic
Drug Class / Mechanism
BCL-2 Inhibitor |
||||
Olverembatinib |
BCR-ABL Tyrosine Kinase Inhibitor | Hematologic (Leukemia) | ||
|
Molecule
Olverembatinib
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Leukemia)
Drug Class / Mechanism
BCR-ABL Tyrosine Kinase Inhibitor |
||||
Oprozomib |
Proteasome Inhibitor | Hematologic (Multiple Myeloma) | ||
|
Molecule
Oprozomib
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Multiple Myeloma)
Drug Class / Mechanism
Proteasome Inhibitor |
||||
JaktinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (MPN)
Drug Class / Mechanism
JAK Inhibitor |
|
LanraplenibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic
Drug Class / Mechanism
SYK / Multi-Kinase Inhibitor |
|
LisaftoclaxTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic
Drug Class / Mechanism
BCL-2 Inhibitor |
|
LY3410738 (IDH1/2 Inhibitor)Targeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (AML)
Drug Class / Mechanism
IDH1/2 Inhibitor |
|
MarizomibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Multiple Myeloma)
Drug Class / Mechanism
Proteasome Inhibitor |
|
MidostaurinTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (AML)
Drug Class / Mechanism
FLT3 Inhibitor |
|
MocetinostatTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Lymphoma)
Drug Class / Mechanism
HDAC Inhibitor |
|
MomelotinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (MPN)
Drug Class / Mechanism
JAK Inhibitor |
|
NavitoclaxTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic
Drug Class / Mechanism
BCL-2 Inhibitor |
|
ObatoclaxTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic
Drug Class / Mechanism
BCL-2 Inhibitor |
|
OlverembatinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Leukemia)
Drug Class / Mechanism
BCR-ABL Tyrosine Kinase Inhibitor |
|
OprozomibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Multiple Myeloma)
Drug Class / Mechanism
Proteasome Inhibitor |
|